Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ePIPAC-OX for unresectable isolated colorectal peritoneal metastases
NL-OMON21399Active, not recruiting
- Sponsor
- Catharina Ziekenhuis
- Start
- Oct 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of oxaliplatin, folinic acid and fluorouracil in colorectal cancer (CRC), Appendiceal carcinoma and peritoneal carcinomatosis (PC), sponsored by Catharina Ziekenhuis. Primary endpoint: Major toxicity. Started Oct 2017; status: active, not recruiting.
02
Drugs
oxaliplatinfolinic acidfluorouracil
03
Conditions
colorectal cancer (CRC)Appendiceal carcinomaperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NL-OMON21399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21399.